Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03391791 · ClinicalTrials.gov registry record
Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors
A clinical trial, sponsored by Adaptimmune.
- Terminated
- Registry status
- 2
- Enrollment target
NCT03391791 is a clinical trial that was terminated before completion, run by Adaptimmune. The registered enrollment target is 2 participants.
The verdict
NCT03391791 was terminated before completion, sponsored by Adaptimmune.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
Subjects who previously took part in an Adaptimmune study and received genetically changed T cells (including but not limited to MAGE-A10ᶜ⁷⁹⁶T and MAGE-A4ᶜ¹º³²T) are asked to take part in this long term follow-up study. Subjects will be asked to join this study once they complete the parent interventional study. The purpose of this study is to find out if the genetically changed T cells that subjects received in the parent study have any long-term side effects. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years starting from last administration of the genetically changed T cells, subjects will visit their study doctor for a check-up and to have blood tests to look for any changes that might have happened because of the genetically changed T cells.
Interventions
- GENETIC Genetically engineered T Cell Receptors
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-02-28 |
| Est. Completion | 2018-07-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03391791
The ClinicalTrials.gov registry entry for NCT03391791 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adaptimmune, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Genetically engineered T Cell Receptors is the first listed.
NCT03391791 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03391791 about?
NCT03391791 is a clinical study titled "Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors". Subjects who previously took part in an Adaptimmune study and received genetically changed T cells (including but not limited to MAGE-A10ᶜ⁷⁹⁶T and MAGE-A4ᶜ¹º³²T) are asked to take part in this long term follow-up study. Subjects will be asked to join this study once they complete the parent interven...
What is the current status of trial NCT03391791?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2018-02-28. Estimated completion is 2018-07-24.
What interventions are being tested in trial NCT03391791?
The interventions under investigation include: Genetically engineered T Cell Receptors (GENETIC).
Who is sponsoring clinical trial NCT03391791?
This trial is sponsored by Adaptimmune, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.